Even if the order takes effect, it will do nothing to address the root causes of the problem it purports to solve.

The S&P 500 climbed by 2.8% on Monday, May 12, 2025 as investors reviewed the trade deal between the U.S. and China that ...

A measure now on the floor of the Nebraska Legislature would address some practices by intermediaries called pharmacy benefit managers that pharmacists say are harming their businesses.

CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...

A White House official said on a press call early Monday that a new executive order from President Trump will push drugmakers ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial. Lilly ...

Omada Health, a virtual chronic care provider, filed to go public Friday, marking the second digital health company making ...

Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss ... patients cannot afford to pay for on their own. The formulary is maintained by CVS ...

Pharmacology has been at it a long time. Precursor to the Western pill-based prescription for all that ails, it stands on the shoulders of a thousands-generations long compilation of the knowledge of ...

Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

Lilly's Zepbound overtook Novo's Wegovy as the leading obesity drug, according to the latest prescription data last month ...

It's unclear how much the CVS formulary change will appeal to employers, especially given that Zepbound is known to be more effective at promoting weight loss than Wegovy. Some patients on the ...